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Oxidant stress in hemodialysis: Prevention and treatment strat- production of inflammatory mediators that in turn stimu-
egies. Oxidant stress has been implicated in a number of pathol- late the production of free radicals. Either the chronic
ogies associated with uremia and hemodialysis. These patients or acute production of free radicals can damage proteins,have an increased incidence of cardiovascular disease, amy-
lipids, DNA, and sugars, as well as biological metabolitesloidosis associated with protein modification, and notable changes
such as creatinine. Production of oxidants and/or freein both function and structure of many cellular components.
Oxidative reactions most frequently involving free radical inter- radicals can also facilitate activation of signaling events
mediates play an important role in these processes and partici- that mediates expression of inflammatory genes [8] as
pate both directly and indirectly by further amplification of the
well as genes regulating cell division [9], differentiationinflammatory responses or in activation of signaling cascades
[10], and apoptosis [11, 12].mediating proliferation, differentiation, and cell death. Proteins
and lipids are susceptible to oxidative degradation. These changes The stimulus in hemodialysis patients can be the he-
can ultimately alter important structural and functional charac- modialysis procedure itself [13]. This can occur by in-
teristics and lead to pathological changes. This article addresses flammatory cell activation caused by bioincompatiblesome of the diverse mechanisms and pathways involved in these
membranes, activation by lipopolysaccharides (LPS) orchanges, and suggests new therapeutic strategies in preventing
oxidative damage. cytokine-inducing substances (CISs), leaching of plasti-
cizers or toxic substances, and damage to erythrocytes
(and subsequent release of small amounts of hemoglo-
Many reports have implicated free radical oxidations bin) by blood pumps or shear stress (Fig. 2). In addition,
and decreased antioxidant defenses in comorbidities as- there is frequently a net loss of antioxidants caused by
sociated with uremia and hemodialysis [1–7]. Cardiovas- diffusive removal of water-soluble antioxidants during a
cular disease is the leading cause of mortality in hemodi- hemodialysis session [14, 15]. The antioxidant defenses
alysis patients, and risk factors such as C-reactive protein can also be further weakened by loss caused by the over-
and lipoprotein (a) are also higher than in the normal production of oxidant free radicals.
population. Free radicals can oxidize low-density lipo-
protein (LDL), increase amyloidosis, damage regulatory
MECHANISMS OF FREEproteins, and suppress erythropoietin gene expression.
RADICAL-MEDIATED DAMAGEThese abnormalities are often further exacerbated in
older or diabetic hemodialysis patients. Although there is strong evidence that hemodialysis
The pathway shared by both hemodialysis and uremia patients have comorbidities related to the imbalance be-
is an amplified inflammatory response (Fig. 1). An initial tween production of oxidants and antioxidant defense,
triggering stimulus can provoke either the production of there is clear disagreement in the literature as to what
inflammatory cytokines or reactive oxygen species such components are affected at the molecular level [such as
as superoxide, hydrogen peroxide, and oxidized lipid lipids, proteins, and advanced glycation end products
mediators. Lack of antioxidant defenses or cellular ma- (AGEs)]. The source of this disagreement often lies in
chinery to shut down this amplified response can lead methodologies employed in the detection of the ele-
to a chronic and vicious cycle of free radicals causing ments leading to oxidant stress [16, 17]. It should be
stressed that the production of free radicals is often local
and transitory. Oxidatively modified proteins or lipidsKey words: antioxidant, free radicals, uremia, end-stage renal failure,
inflammatory response. frequently undergo further chemical modification/degra-
dation or metabolism, and the usual laboratory proce-Ó 2000 by the International Society of Nephrology
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Fig. 1. Amplified inflammatory response. Free
radicals can cause an amplification of the in-
flammatory response by stimulating further
production of cytokines and inflammatory me-
diators.
Fig. 2. Free radical production. Bioincompati-
ble membrane, lipopolysaccharide (LPS), or
cytokine-inducing substances (CISs) can acti-
vate inflammatory cells to produce free radicals
and oxidant species. This can lead to oxidation
of circulating proteins (such as albumin) with
eventual proteolytic degradation or protein
cross-linking; oxidation of LDL and damage to
erythrocytes causing microhemolysis. Oxidant
stress is also more likely to occur in hemodialy-
sis patients because of loss of the water-soluble
antioxidants, uric acid, and vitamin C.
dures for oxidized lipid or protein lack either the sensitiv- example of a protein, we might see changes in the tertiary
structure, which expose labile or hydrophobic sites thatity or the specificity.
Dysfunctional or sublethal damage occurs as one of are normally well hidden. This may make the protein
more susceptible to proteolytic cleavage, cross-linking,the first early reversible changes. Cell and plasma compo-
nents can slowly accumulate low levels of toxic com- or chemical modification. Oxidatively modified proteins
and lipids can frequently undergo repair processes (inpounds such as phospholipid hydroperoxides, choles-
terol oxides, AGEs, or advanced lipid end products which the modified component is either repaired or elim-
inated by repair enzymes) [19]. Normal cells often recog-(ALEs) [18]. Uremic toxins may also cause conforma-
tional or functional changes of proteins. If we take the nize these dysfunctional sites and attempt to repair or
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eliminate the damaged component. Phospholipase A2 that heparin could bind and promote the oxidation of
albumin, thus increasing its susceptibility to tryptic diges-can recognize and cleave oxidatively modified phospho-
lipids, while mildly oxidized proteins have increased sus- tion [23]. This effect was further increased in the pres-
ence of glucose. Heparin also binds to LDL, and a recentceptibility to proteolysis in which the oxidized protein
can be eliminated [20]. In the absence of the repair pro- article by Upritchard and Sutherland found that LDLs
complexed to heparin or glycosaminoglycans were highlycesses, these low levels of oxidized lipids or proteins can
actually be an important stimulus or source for further susceptible to oxidation by peroxidases, with particular
enhancement by low levels of water soluble antioxidantsfree radical production.
One of the obvious goals in measuring oxidative dam- [24]. Another recent article suggested that intravenous
iron may play a role in lipid peroxidative damage andage is to identify and quantitate specific biomarkers that
are stable end products. It should be noted that there modulation of antioxidant secondary defense enzymes
[25]. These authors observed a higher level of lipid perox-are many different pathways involved in the formation
of these products and that these oxidatively modified idation and lowered superoxide dismutase (SOD) activ-
ity in patients with baseline ferritin levels above 601 mg/L.proteins and lipids can be further degraded and modified
or undergo transformation by cross-linking or forming The host is protected from free radicals by an antioxi-
dant defense system that employs different chemicalsadducts with other products. This presents problems in
determining appropriate markers of oxidant stress, as and enzymes to: (1) scavenge free radicals; (2) work in
synergy to maintain other antioxidants in a reduced orthese products do not always occur at the same rates of
formation or the same extent, nor do all of the products active state, such as glutathione sulfhydryl (GSH) or
ascorbic acid; or (3) by the use of enzymes that “cleanhave the same level of stability. Several endogenous sub-
stances can also interfere with measurements and often up” or degrade oxidatively modified proteins, lipids, or
DNA. In addition, at the molecular level, the activationgive artificially high or biased results [21]. Examples in-
clude the interference of several sugars with the measure- of nuclear factor-kB (NF-k is modulated by free radicals
ment of malondialdehyde, dietary sources of conjugated oxidants and antioxidants [26]. The defense system is
dienes, which can be mistakenly attributed to the conju- finely tuned and works to maintain control over excess
gated diene formation associated with lipid hydroperox- free radicals that are produced during pathologic or
ides [17], and interference from plasma scattering, hemo- physiologic processes. In hemodialysis patients, ascorbic
lysis, or endogenous substances for spectroscopic assays. acid is generally much lower than healthy controls (even
Another problem is that the products of free radical predialytically) and is lost further during a dialysis ses-
damage are often localized or transitory. Examples of sion. Uric acid (a quite effective antioxidant) is increased
localized damage include the oxidation of LDL in the predialytically and eventually falls to normal levels at
subendothelial space or oxidation of b2-microglobulin in the end of a dialytic session. Total plasma vitamin E is
amyloid plaques. The transitory nature can be due to at nearly the same level as healthy controls; however,
further chemical reactions by the oxidized product (such erythrocyte and LDL vitamin E have been reported to
as the cross-linking of apoB100 with oxidized hemoglo- be lower, and several antioxidant enzymes such as SOD
bin or the degradation of lipid hydroperoxides). and glutathione peroxidase have increased activity.
Oxidative modifications found in plasma components
can usually be attributed to the release of hypochlorous
BIOLOGICAL COMPONENTS SUSCEPTIBLE TOacid, hydrogen peroxide, and superoxide from activated
OXIDANT STRESSinflammatory cells. These reactive species can directly
Oxidant stress and antioxidant defenses are balanceddamage proteins or lipids or react with other substances
in a healthy individual. This concept of “balance” is some-such as free hemoglobin or nitric oxide to form new
times oversimplified. Frequently, oxidant stress is evalu-oxidants. Transition metals can also contribute to radical
ated in terms of a “total quantity of oxidized products”production rate in the presence of protein or lipid hydro-
or “total quantity of antioxidants.” This commonly leadsperoxides. It was recently suggested that free heme re-
to errors in either underestimating or overestimatingleased during microhemolysis may form a reactive ty-
the physiological importance of the oxidant stress. Inrosyl radical that can lead to protein modification and
practical terms, many free radicals are produced at localcross-linking [22]. A relevant consequence of the interac-
sites, and relatively low levels of oxidant stress can theo-tion of nitric oxide with either hemoglobin or superoxide
retically cause grave damage if essential proteins or bio-is also the loss of the vasodilating effect.
logical components are modified. Vice versa, damage toDifferent pharmaceutical agents can also influence ox-
biological components with relatively low physiologicalidative modifications, especially if delivered during dial-
importance, high turnover, or molecules that are easilyysis near the beginning with increased activation or near
repaired may cause only minor pathological inconve-the end of a session when the concentration of water
soluble antioxidants are low. Finotti and Pagetta found nience. This section discusses some of the critical biologi-
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cal components that are possibly changed during periods such as tyrosine (with the formation of a tyrosyl radical)
can modify LDL and possibly other proteins such asof oxidant stress in hemodialysis patients.
albumin or other circulating proteins.
LOW DENSITY LIPOPROTEIN
ALBUMIN AND OTHER PLASMA PROTEINSLow-density lipoprotein is susceptible to free radical
injury, and modified LDL has been suggested to be im- Albumin has been suggested to function as the most
important and predominant circulating plasma antioxi-portant in the development of atherosclerotic lesions.
Oxidative modification of LDL can range from mild to dant [36, 37]. This is due to its high total number of free
sulfhydryl groups and its relatively short half-life (aboutsevere, and the extent of modification can influence prop-
erties such as cytotoxicity and uptake regulated by the 20 days). The free cysteine residue at amino acid 34 also
carries reduced glutathione and over 80% of the plasmascavenger receptor. Mild oxidation can cause the forma-
tion of a more electronegative species termed LDL–. free nitric oxide [38]. Bilirubin bound to albumin has also
been shown to be an effective antioxidant and protectedThis modified LDL has increased atherogenicity, in-
creased susceptibility to oxidation, and impaired metab- a-tocopherol from damage mediated by peroxyl radicals
[39]. Albumin also protects linoleic acid (either free orolism. It was recently reported by Ziouzenkova et al that
levels of LDL– were elevated in hemodialysis patients in low density lipoprotein) [40].
Albumin can be easily oxidized with hypochlorous[22]. It has been also observed that in LDL–, apoB is
almost completely unfolded and that this loss of structure acid and hydrogen peroxide. Additionally, heparin in
the presence of glucose causes oxidation and proteolyticleads to sinking of the apoprotein in the lipid core of
LDL (Fulvio Ursini, personal communication) cleavage. The biological effects of oxidized albumin are
not well characterized. It does appear that either oxidationMaggi et al found increased antibodies to epitopes
produced during copper and malondialdehyde (MDA)- or glycation can severely impair the antioxidant proper-
ties and, under certain circumstances, can even causemodified LDL in dialysis subjects with respect to control
subjects [27]. Oxidation of LDL may be important in albumin to have pro-oxidant activities [41]. These authors
suggested that in addition to albumin concentration, in-hemodialysis patients, as they have 10 to 20 times the
risk for cardiovascular problems compared with healthy, tegrity may be the key determinant in its protective func-
tion as an antioxidant. Mild oxidation may also increaseage-matched controls. Oxidized LDL can interact and
inactivate nitric oxide, and thus influencing vascular tone, the proteolytic susceptibility. Kausler and Spiteller found
fragments of albumin and b2-microglobulin in the hemo-it induces apoptosis in cultured human umbilical endo-
thelial cells and in smooth muscle cells of isolated aorta filtrate of uremic patients that were not found in the
plasma of healthy controls [42]. These fragments ap-[28, 29]. Oxidized LDL also stimulates O2x2 production [30].
peared to be from proteolytic degradation.
b2-Microglobulin extracted from amyloid fibrils alsoERYTHROCYTES shows limited proteolysis (.20%) [43]. Modifications to
Erythrocytes from hemodialysis patients have in- b2-microglobulin include glycation, oxidative modifica-
creased levels of MDA and decreased levels of vitamin tion, modification by (carboxymethyl)lysine, or deamina-
E [31, 32]. In addition, erythrocytes from uremic patients tion of Asn 17. Protein synthesis and catabolism normally
have a shortened life span with respect to healthy con- exist in concert to promote optimal concentration and
trols [33]. Changes in osmotic fragility are also more performance. Modifications can cause a dysequilibrium
common in hemodialysis patients [33, 34]. How might and thus increase the possibility of premature turnover,
these changes ultimately affect hemodialysis patients? protein aggregation, and incorrect function.
First, oxidative damage to the erythrocyte membrane
can cause the formation of microdomains that affect the
NEW THERAPEUTIC STRATEGIES TOcytoskeleton and erythrocyte shape. Oxidation can also
REDUCE OXIDANT STRESScause erythrocytes to lose membrane asymmetry with
the appearance of phosphatidylserine in the outer mem- Therapeutic approaches to minimize oxidant stress
during hemodialysis should focus on reduction of in-brane leaflet [35]. Both shape (morphometric) and loss
of asymmetry increase erythrocyte turnover and seques- flammatory cell activation, removal of inflammatory me-
diators, and maintenance of host antioxidant defenses.tration by the spleen. Increased susceptibility to damage
or rupture can also cause a release of small quantities This approach can start with the use of biocompatible
membranes (and blood lines) and the use of ultrapureof hemoglobin, referred to as microhemolysis. While this
small quantity of released hemoglobin may be consid- dialysate. Reduction of initial inflammatory cell stimulus
is important for preventing the amplified inflammatoryered to have a negligible impact on anemia, the very
reactive nature of the heme and associated amino acids response.
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Fig. 3. Hemolipodialysis (HLD). HLD uses li-
posomes added to the dialysate to remove hy-
drophobic substances and protein-bound tox-
ins, and to reduce oxidant stress. Vitamin E is
incorporated into the liposome bilayer, while
vitamin C is added directly to the dialysate.
Active lipid mediators, AGEs, oxidatively modified unilamellar bilayer upon addition of physiological buffer
or dialysate.proteins, or protein products can stimulate inflammation
and serve to amplify many of the inflammatory processes. Since oxidants can trigger the production of other cy-
tokines and inflammatory mediators, one of the thera-Recently, new approaches have also been suggested for
removing or adsorbing inflammatory mediators. This can peutic strategies of HLD is to prevent an overproduction
of free radicals or a compromise to the hosts’ antioxidantbe achieved by membranes that allow diffusive, adsorp-
tive, or convective clearance of these substances from defenses. The antioxidant protection is provided by the
addition of vitamin E to the liposome bilayer and thethe plasma or by purification of ultrafiltrate or plasma
by passage through activated carbon or resin [44, 45]. addition of water-soluble vitamin C to the dialysate.
These two antioxidants are used together to synergisti-Hemolipodialysis (HLD) has recently been proposed
to modify oxidant stress by modification of inflammatory cally support the patient’s antioxidant defense system.
Ascorbic acid can recycle a-tocopherol from the tocoph-cell activation, removal of inflammatory mediators, and
maintenance of antioxidants [46, 47]. HLD exploits the eroxyl free radical, thus maintaining vitamin E in its
active form. These two well-characterized antioxidantsamphipathic nature of liposomes added to the dialysate
to increase removal of hydrophobic toxins and to func- work together to scavenge antioxidants and to maintain
a-tocopherol in its reduced (active) state [36, 48].tion together with a-tocopherol (vitamin E) and ascorbic
acid (vitamin C) to reduce oxidant stress (Fig. 3). The Several well-controlled studies have demonstrated
that ascorbate is the most effective aqueous-phase anti-primary goal is to prevent activation of inflammatory
cells and an amplified inflammatory response. The lipo- oxidant in plasma and human blood [48], and that the
temporal disappearance during oxidative stress, in rela-somes used in HLD are approximately 250 to 300 nm
in diameter, which allows interaction at the asymmetric tionship to the formation of lipid hydroperoxides (during
a constant flux of aqueous free radicals), occurs in thisinterface of polysulfone membrane pores without actual
passage through the membrane. They are comprised of order: ascorbate . protein thiols . urate . a-tocopherol
(same). Hemodialysis patients, in addition to havingthe unsaturated phospholipid, soybean phosphatidylcho-
line in a lyophilized form, which spontaneously form a lower than normal levels of plasma ascorbate, have a
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